dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Lipton, Richard B |
dc.contributor.author | Pozo Rosich, Patricia |
dc.contributor.author | Blumenfeld, Andrew M |
dc.contributor.author | Li, Ye |
dc.contributor.author | Severt, Lawrence |
dc.contributor.author | Stokes, Jonathan |
dc.date.accessioned | 2023-04-25T07:54:58Z |
dc.date.available | 2023-04-25T07:54:58Z |
dc.date.issued | 2023-02-21 |
dc.identifier.citation | Lipton RB, Pozo-Rosich P, Blumenfeld A, Li Y, Severt L, Stokes JT, et al. Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial. Neurology. 2023 Feb 21;100(8):e764–77. |
dc.identifier.issn | 1526-632X |
dc.identifier.uri | https://hdl.handle.net/11351/9412 |
dc.description | Atogepant; Tractament preventiu; Migranya |
dc.description.sponsorship | Allergan, now AbbVie, sponsored the study. |
dc.language.iso | eng |
dc.publisher | Wolters Kluwer Health |
dc.relation.ispartofseries | Neurology;100(8) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Migranya - Prevenció |
dc.subject | Pacients - Satisfacció |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Migraine Disorders |
dc.subject.mesh | /prevention & control |
dc.subject.mesh | Patient Reported Outcome Measures |
dc.subject.mesh | Double-Blind Method |
dc.title | Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1212/WNL.0000000000201568 |
dc.subject.decs | trastornos migrañosos |
dc.subject.decs | /prevención & control |
dc.subject.decs | medidas de resultados percibidos por los pacientes |
dc.subject.decs | método doble ciego |
dc.relation.publishversion | https://doi.org/10.1212/WNL.0000000000201568 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Lipton RB] Albert Einstein College of Medicine and the Montefiore Headache Center, Bronx, NY. [Pozo-Rosich P] Unitat de Cefalea, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca de Cefalea i Dolor Neurològic, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma of Barcelona, Bellaterra, Spain. [Blumenfeld AM] Headache Center of Southern California, Carlsbad, CA. [Li Y, Severt L, Stokes JT] AbbVie, Madison, NJ, USA |
dc.identifier.pmid | 36396451 |
dc.identifier.wos | 000943191900011 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |